Overview

• The overhaul will eliminate about 9,000 positions, roughly 11–11.5% of staff, with around 5,000 cuts in Denmark.
• Novo Nordisk targets approximately 8 billion Danish kroner in annual savings by the end of 2026 and expects about €1.2 billion in third‑quarter restructuring charges.
• Operating‑profit growth guidance for 2025 has been reduced to 4–10% from 10–16%.
• New CEO Mike Doustdar says the reorganization will streamline decision‑making and refocus spending on diabetes and obesity therapies.
• Executives point to mounting rivalry—particularly from Eli Lilly’s treatments—plus patent expiries and cheaper copycats, and the shares fell on the announcement.